122 related articles for article (PubMed ID: 22622559)
1. Microbiology: Categorize probiotics to speed research.
Reid G
Nature; 2012 May; 485(7399):446. PubMed ID: 22622559
[No Abstract] [Full Text] [Related]
2. FDA not NIH can speed new drugs.
Miller HI
Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
[No Abstract] [Full Text] [Related]
3. Translational medicine and the National Institutes of Health road map: steep grades and tortuous curves.
Humes HD
J Lab Clin Med; 2005 Aug; 146(2):51-4. PubMed ID: 16099234
[No Abstract] [Full Text] [Related]
4. The 21st Century Cures Act--Will It Take Us Back in Time?
Avorn J; Kesselheim AS
N Engl J Med; 2015 Jun; 372(26):2473-5. PubMed ID: 26039522
[No Abstract] [Full Text] [Related]
5. Reform bill to speed drugs to residents.
Hawryluk M
Provider; 1997 Nov; 23(11):37-8. PubMed ID: 10173669
[No Abstract] [Full Text] [Related]
6. New drug law to speed scientific review.
Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
[TBL] [Abstract][Full Text] [Related]
7. Business considerations in the development of probiotics.
Hoffman FA
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S141-3; discussion S144-51. PubMed ID: 18181721
[TBL] [Abstract][Full Text] [Related]
8. Epo, by any other name.
Nature; 2007 Sep; 449(7160):259. PubMed ID: 17882170
[No Abstract] [Full Text] [Related]
9. Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification.
Mattia A; Merker R
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S115-8; discussion S144-51. PubMed ID: 18181714
[TBL] [Abstract][Full Text] [Related]
10. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
11. 21st Century Cures Act-A Cure-All for Patients?
Wallis L
Am J Nurs; 2016 Jul; 116(7):19-20. PubMed ID: 27336981
[TBL] [Abstract][Full Text] [Related]
12. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
Novak E; Allen PJ
Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
[TBL] [Abstract][Full Text] [Related]
13. The regulation of drugs and biologics: fifty years into the future.
Kuhlik BN
Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
[No Abstract] [Full Text] [Related]
14. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
O'Reilly JT
Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
[No Abstract] [Full Text] [Related]
15. Environmental assessment requirements for live biological drugs.
Sutton A
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S112-4; discussion S144-51. PubMed ID: 18181713
[TBL] [Abstract][Full Text] [Related]
16. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
17. European investigational antiepilepsy drug trials.
Sussman NM
Epilepsy Res Suppl; 1993; 10():149-55. PubMed ID: 8251090
[No Abstract] [Full Text] [Related]
18. The domestic drug regulatory process: why time is of the essence.
Katz R
Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109
[No Abstract] [Full Text] [Related]
19. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
Lang L
Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
[No Abstract] [Full Text] [Related]
20. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
[Next] [New Search]
